Amplia Therapeutics Ltd (ATX)

Snapshot

ATX's Principal Activity is the development of Focal Adhesion Kinase (FAK) inhibiting drug candidates AMP886 and AMP945.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Ms S Jane Catherine Bell	Non-Executive Director	Apr 2021	Ms S Jane Catherine Bell Non-Executive Director Ms Bell is a non-executive director with more than 30 years' experience in law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Jane has been a non-executive director since 2002, serving on 12 boards including nine health and medical research boards. Jane currently serves as Deputy Chair of Monash Health, Director of Jessie McPherson Private Hospital, Chair of the Community Advisory Group of the Melbourne Genomics Health Alliance and is a Member of the Administrative Appeals Tribunal. Jane is a former Chair of Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy Chair of Westernport Water Corporation, Director of UCA Funds Management, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of Medical Research-Prince Henry's Institute of Medical Research, Queensland Institute of Medical Research Trust, Australian Red Cross (Qld) and Victorian Women's Housing Association.
Dr John Lambert	Chief Executive Officer,Managing Director	Jun 2019	Dr John Lambert Chief Executive Officer,Managing Director Dr Lambert has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, John was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry John was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). John is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
Dr Warwick Bonner Tong	Non-Executive Director,Non-Executive Chairman	May 2018	Dr Warwick Bonner Tong Non-Executive Director,Non-Executive Chairman Dr Tong is a NZ trained physician with more than 25 years experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice Warwick has held a wide variety of roles in the pharmaceutical and biotech industry in NZ(Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). Warwick currently serves as director of Aculeus Therapeutics Pty Ltd, CannaPacific Pty Ltd and its affiliate e3D Pharma Pty Ltd. He is a member of the Strategic Advisory Board of the Maurice Wilkins Centre in Auckland NZ and of the CSIRO Manufacturing Business Advisory Committee. Warwick is a former CEO and director of CTx, director and Chair of the CTx commercialisation company, CTxONE, and director and Chair of BioMedVic.
Dr Christopher John Burns	Non-Executive Director	May 2018	Dr Christopher John Burns Non-Executive Director Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years. After completing a PhD in Organic Chemistry at the University of Melbourne Chris undertook post-doctoral studies in the USA before moving to Pfizer UK, where he worked on a variety of drug discovery projects. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech as Head of Medicinal Chemistry and later as Research Director. During this time he led teams in the discovery of two anti-cancer agents that have entered clinical trial, including the drug momelotinib which successfully completed Phase III studies. Most recently Chris was a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research in Melbourne and currently holds executive roles with privately held biotechs MecRx, Certa Therapeutics and OccuRx. Dr Burns is the inventor on over 30 patents and a co-author on over 50 scientific publications.
Dr Robert Peach	Non-Executive Director	Sep 2015	Dr Robert Peach Non-Executive Director Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos Limited, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for US$7.8B. Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is currently on the Board of Directors of AdAlta Pty Limited and Rekover Therapeutics, and serves on the Scientific Advisory Board of Eclipse Bioinnovations. Robert is the co-author of 70 scientific publications and book chapters, and 26 patents and patent applications.
Mr Andrew John Cooke	Company Secretary	Oct 2013	Mr Andrew John Cooke Company Secretary Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
Jeff Carter	Chief Financial Officer	N/A
Mark Devlin	Chief Science Officer	N/A
Rhiannon Jones	Director, Operations	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
02/09/21	S Jane Bell	Buy	+557,646	$0.207	$115,432	On-market trade
01/09/21	S Jane Bell	Buy	+36,268	$0.19	$6,890	On-market trade
07/06/21	John Lambert	Issued	130,000	$0.155	$20,150	Exercise of options
07/06/21	John Lambert	Exercise	130,000	$0.155	$20,150	Exercise of options
18/09/20	Robert Peach	Issued	275,808	$0.127	$35,000	Director remuneration
18/09/20	Christopher Burns	Issued	197,006	$0.127	$25,000	Director remuneration
18/09/20	Warwick Tong	Issued	413,712	$0.127	$52,500	Director remuneration
04/08/20	John Lambert	Issued	120,000	$0.10	$12,000	Rights issue
04/08/20	Warwick Tong	Issued	150,000	$0.10	$15,000	Rights issue
13/07/20	Warwick Tong	Issued	200,000	$0.10	$20,000	Rights issue
17/09/19	Robert Peach	Transfer	56,000	$0.08	$4,480	Off-market transfer
17/09/19	Robert Peach	Issued	500,000	$0.08	$40,000	Placement
17/09/19	Robert Peach	Transfer	56,000	$0.08	$4,480	Off-market transfer
17/09/19	Christian Behrenbruch	Issued	125,000	$0.08	$10,000	Placement
17/09/19	Warwick Tong	Issued	125,000	$0.08	$10,000	Placement
17/09/19	Christian Behrenbruch	Issued	250,000	$0.10	$25,000	Placement
17/09/19	Warwick Tong	Issued	250,000	$0.10	$25,000	Placement
17/09/19	Robert Peach	Issued	1,000,000	$0.10	$100,000	Placement
20/08/19	Simon Wilkinson	Expiry	175,000	$0.077	$13,475	Options expired
02/08/19	Warwick Tong	Issued	80,000	$0.10	$8,000	Rights issue
02/08/19	Christopher Burns	Issued	30,000	$0.098	$2,940	Rights issue
02/08/19	Warwick Tong	Issued	40,000	$0.098	$3,920	Rights issue
02/08/19	Andrew Cooke	Issued	63	$0.098	$6	Rights issue
02/08/19	Andrew Cooke	Issued	125	$10.001	$1,250	Rights issue
02/08/19	Christopher Burns	Issued	60,000	$0.10	$6,000	Rights issue
06/11/18	Andrew Cooke	Buy	+120	$0.31	$37	Off-market trade
05/11/18	Simon Wilkinson	Expiry	100,000	$0.27	$27,000	Options expired

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
S Jane Bell	02/09/2021	277,163	593,914	N/A	N/A
John Lambert	07/06/2021	130,000	220,000	1,870,000	N/A
Christopher Burns	31/03/2021	2,472,243	N/A	30,000	N/A
Warwick Tong	31/03/2021	2,755,140	N/A	165,000	N/A
Robert Peach	31/03/2021	N/A	1,331,808	980,000	N/A
Andrew Cooke	06/02/2020	375	N/A	480,063	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
HSBC Custody Nominees (Australia) Limited	20,374,618	16.32%
Bond Street Custodians Limited <Lam1 D08047 A/C>	8,750,000	7.01%
Citicorp Nominees Pty Limited	5,803,803	4.65%
BNP Paribas Noms Pty Ltd <Drp>	4,595,985	3.68%
Ctxt Pty Ltd	4,514,468	3.62%
Elk River Holdings Pty Ltd	2,942,142	2.36%
Christopher John Burns	2,472,243	1.98%
Warwick Tong	2,355,140	1.89%
34Th Avenue Pty Ltd <Devlin Family A/C>	2,215,237	1.77%
Gp Securities Pty Ltd	1,930,000	1.55%
Mr Andrew Podolak	1,925,000	1.54%
Mark Sullivan <Aems Consulting A/C>	1,661,428	1.33%
Cancer Research Technology Limited	1,360,524	1.09%
HWH Power Pty Ltd <Hwh Super Fund A/C>	1,270,000	1.02%
Merrill Lynch (Australia) Nominees Pty Limited	1,058,057	0.85%
Cofactor Llc	1,000,000	0.80%
Swanmark Super Pty Ltd <Rc Swan Super Fund A/C>	1,000,000	0.80%
Ravinna Pty Ltd <Ravinna A/C>	993,992	0.80%
Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C>	940,000	0.75%
Margaret Frame	923,016	0.74%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.125	30 June
2019	$0.097	28 June

ATX Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.